Tag

Dyslipidemia

All articles tagged with #dyslipidemia

New US Guidelines Push Early Lipid Control to Fight Heart Disease
health20 days ago

New US Guidelines Push Early Lipid Control to Fight Heart Disease

US cardiologists updated the 2018 cholesterol guidelines, emphasizing earlier treatment of dyslipidemia to cut lifetime ASCVD risk. Key changes include screening starting in childhood (as young as 9–11, potentially earlier with family history), a new PREVENT risk calculator to personalize 10-year and 30-year cardiovascular risk, LDL targets of <100 mg/dL for borderline/intermediate risk, <70 mg/dL for high risk, and <55 mg/dL for very high risk, and a broader use of therapies (statins and other lipid-lowering drugs) alongside lifestyle changes to reduce long-term heart attack and stroke risk.

Cholesterol guidelines tighten focus on early prevention and personalized risk
cardiovascular-health5 months ago

Cholesterol guidelines tighten focus on early prevention and personalized risk

The American Heart Association and American College of Cardiology have updated dyslipidemia guidelines, prioritizing earlier lifestyle-based prevention, a modern cardiovascular risk calculator (PREVENT) to guide treatment, and additional tests (CAC, Lp(a), ApoB) to refine risk and LDL-C lowering decisions; the updates also address hypertriglyceridemia therapies and recommend cholesterol screening for kids aged 9–11 to identify familial hypercholesterolemia early and reduce lifetime cardiovascular risk.

AHA's 2026 Dyslipidemia Guideline: Start Screening Early for Lifelong Heart Health
health5 months ago

AHA's 2026 Dyslipidemia Guideline: Start Screening Early for Lifelong Heart Health

The AHA and ACC released the 2026 Guideline on the Management of Dyslipidemia, shifting from older risk scores to the PREVENT-ASCVD calculator to estimate 10- and 30-year ASCVD risk and emphasize lifelong heart-risk reduction through earlier screening and personalized therapy. It highlights measuring biomarkers like Lp(a) and ApoB, using coronary artery calcium scoring, and keeping statins as first-line therapy with new lipid-lowering options, advocating for earlier intervention—especially in younger adults—to reduce future heart attack and stroke risk.

2026 Lipid Guidelines Use PREVENT Scores to Tailor Therapy
health5 months ago

2026 Lipid Guidelines Use PREVENT Scores to Tailor Therapy

The 2026 American dyslipidemia guideline endorses PREVENT-ASCVD risk equations to guide primary prevention therapy and suggests considering lipid-lowering treatment for adults at intermediate risk based on a 10-year PREVENT-ASCVD risk, with additional considerations for borderline risk and for patients with moderate subclinical atherosclerosis, aiming to lower LDL cholesterol.

2026 ACC/AHA Dyslipidemia Guideline Emphasizes Early Intervention and PREVENT-ASCVD
health5 months ago

2026 ACC/AHA Dyslipidemia Guideline Emphasizes Early Intervention and PREVENT-ASCVD

The 2026 ACC/AHA Guideline on Dyslipidemia consolidates evidence-based recommendations, retires the 2018 cholesterol guideline, and stresses earlier lifestyle measures from childhood along with earlier pharmacotherapy for familial hypercholesterolemia and high LDL-C. It also adopts the PREVENT-ASCVD risk equations to guide lipid-lowering therapy in adults aged 30–79, aiming to improve ASCVD prevention.

New ACC/AHA Dyslipidemia Guideline Promotes Early Lifestyle Action and Risk-Tailored Therapy
heart-news5 months ago

New ACC/AHA Dyslipidemia Guideline Promotes Early Lifestyle Action and Risk-Tailored Therapy

The ACC, AHA and partners released an updated dyslipidemia guideline that emphasizes earlier lifestyle changes, lower LDL-C targets based on individual risk, and earlier use of lipid-lowering therapies; it introduces the PREVENT-ASCVD risk calculator for primary prevention, expands testing for lipids including lipoprotein(a) and apolipoprotein B, and recommends selective use of coronary calcium scoring to guide treatment decisions, with guidance extending to pediatric screening and different populations to reduce lifetime ASCVD risk.